1. Home
  2. OGN vs JANX Comparison

OGN vs JANX Comparison

Compare OGN & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Organon & Co.

OGN

Organon & Co.

HOLD

Current Price

$6.41

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo Janux Therapeutics Inc.

JANX

Janux Therapeutics Inc.

HOLD

Current Price

$13.97

Market Cap

790.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OGN
JANX
Founded
1923
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
790.3M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
OGN
JANX
Price
$6.41
$13.97
Analyst Decision
Hold
Strong Buy
Analyst Count
4
11
Target Price
$11.75
$53.60
AVG Volume (30 Days)
3.9M
786.3K
Earning Date
05-14-2026
06-01-2026
Dividend Yield
1.24%
N/A
EPS Growth
N/A
N/A
EPS
0.72
N/A
Revenue
$6,216,000,000.00
$10,000,000.00
Revenue This Year
$0.42
N/A
Revenue Next Year
$1.67
$209.90
P/E Ratio
$8.98
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.18
$12.12
52 Week High
$15.88
$35.34

Technical Indicators

Market Signals
Indicator
OGN
JANX
Relative Strength Index (RSI) 31.55 54.01
Support Level $6.34 $13.80
Resistance Level $7.87 $15.49
Average True Range (ATR) 0.30 0.51
MACD -0.09 0.13
Stochastic Oscillator 7.89 73.91

Price Performance

Historical Comparison
OGN
JANX

About OGN Organon & Co.

Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.

About JANX Janux Therapeutics Inc.

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Share on Social Networks: